FSME-IMMUN Junior susp inj aig sép ser pré 0.25 ml

7680006830035 CH-683 J07BA01 08.08.
FSME-IMMUN Junior susp inj aig sép ser pré 0.25 ml
FSME-IMMUN Junior susp inj aig sép ser pré 0.25 ml
FSME-IMMUN Junior susp inj aig sép ser pré 0.25 ml
1 / 3
google

Details

Product number
0068301
CPT
-
Packaging group
1
Unit
Fertigspritze(n)
Composition
virus FSME inactivatus (Stamm Neudörfl) 1.19 µg, aluminii hydroxidum hydricum ad adsorptionem corresp. aluminium 0.17 mg, albuminum seri humani, natrii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.25 ml corresp. natrium 0.71 mg et kalium 0.007 mg, residui: saccharum, formaldehydum, protamini sulfas, neomycinum, gentamicinum.

Articles (1)

FSME-Immun 0.25 ml Junior, Injektionssuspension in einer Fertigspritze
Injektionssuspension
1
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Professional SmPC
Allemand
20/08/2021
Professional SmPC
Français
20/08/2021
Professional SmPC
Italien
20/08/2021

Detailed composition

Substance Quantity Type Category
(N/A)
1.19 UG Substance Wirkstoff (Principe actif)
(N/A)
- Substance HNIDK
(N/A)
0.17 MG Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
0.71 MG Substance HBESI
(N/A)
0.007 MG Substance HBESI
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK

Reimbursement information

Public price
CHF 45.55
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/01/2017

Authorization holder

Pfizer AG

8052 Zürich

Authorization information

Swissmedic authorization number
683
Drug name
FSME-Immun 0.25 ml Junior, Injektionssuspension in einer Fertigspritze
Galenic form
SUPA
ATC Code
J07BA01
Authorization status
Z
Dispensation category
B
First authorization
10/10/2003
Authorization expiration date
31/12/9999
IT number
08.08.
Domain
Human medicine
Field of application
aktive Immunisierung gegen Frühsommer-Meningoenzephalitis, ab dem vollendeten 1. bis zum vollendeten 16. Lebensjahr

Packaging details

Description (FR)
FSME-IMMUN Junior susp inj aig sép ser pré 0.25 ml
Description (DE)
FSME-IMMUN Junior Inj Susp sep Nad Fertspr 0.25 ml
Market launch
10/10/2003
Narcotic (BTM)
No

Application methods

IMU

Other packaging sizes

FSME-IMMUN Junior susp inj s ai 10 ser pré 0.25 ml
10 FESP
View